Vancouver, BC – January 23, 2018 – InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at Canaccord Genuity’s 2nd Annual Cannabis Investor Day taking place at The Fairmont Waterfront Hotel in Vancouver, BC, on Wednesday, January 24, 2018.
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Contact: InMed Pharmaceuticals Inc.
Chris Bogart
Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.